The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects

被引:11
作者
Tanno, Luciana Kase [1 ]
Kerr, Daniel Shikanai [2 ,5 ]
dos Santos, Bernardo [4 ]
Talib, Leda Leme [2 ,5 ]
Yamaguti, Celia [3 ]
Rodrigues, Helcio [3 ]
Gattaz, Wagner Farid [2 ,5 ]
Kalil, Jorge [1 ,3 ]
机构
[1] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil
[2] Univ Sao Paulo, Inst Psychiat, Lab Neurosci LIM 27, Sao Paulo, Brazil
[3] Univ Sao Paulo, Clin Immunol & Allergy Div, Lab Immunol LIM 19, Sao Paulo, Brazil
[4] Univ Sao Paulo, Sch Nursing, Sao Paulo, Brazil
[5] Univ Sao Paulo, Ctr Interdisciplinary Res Appl Neurosci NAPNA, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
STEVENS-JOHNSON-SYNDROME; MICROSOMAL EPOXIDE HYDROLASE; CARBAMAZEPINE; PHENOTYPE; EXPRESSION; VARIANTS; EPILEPSY;
D O I
10.1371/journal.pone.0136141
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Although aromatic anticonvulsants are usually well tolerated, they can cause cutaneous adverse drug reactions in up to 10% of patients. The clinical manifestations of the antiepileptics-induced hypersensitivity reactions (AHR) vary from mild skin rashes to severe cutaneous drug adverse reactions which are related to high mortality and significant morbidity. Genetic polymorphisms in cytochrome P450 genes are associated with altered enzymatic activity and may contribute to the risk of AHR. Here we present a case-control study in which we genotyped SNPs of CYP2C19, 2C9 and 3A5 of 55 individuals with varying severities of AHR, 83 tolerant, and 366 healthy control subjects from Sao Paulo, Brazil. Clinical characterization was based on standardized scoring systems and drug patch test. All in vivo investigation followed the ENDA (European Network of Drug Allergy) recommendations. Genotype was determined by real time PCR using peripheral blood DNA as a template. Of all 504 subjects, 65% were females, 45% self-identified as Afro-American, 38% as Caucasian and 17% as having non-African mixed ascendancy. Amongst 55 subjects with AHR, 44 had severe cutaneous drug adverse reactions. Of the 46 drug patch tests performed, 29 (63%) were positive. We found a strong association between the absence of CYP3A5*3 and tolerant subjects when compared to AHR (p = 0.0002, OR = 5.28 [CI95% 2.09-14.84]). None of our groups presented positive association with CYP2C19 and 2C9 polymorphisms, however, both SNPs contributed to separation of cases and tolerants in a Classification and Regression Tree. Our findings indicate that drug metabolism genes can contribute in the tolerability of antiepileptics. CYP3A5*3 is the most prevalent CYP3A5 allele associated with reduced enzymatic function. The current study provides evidence that normal CYP3A5 activity might be a protective factor to aromatic antiepileptics-induced hypersensitivity reactions in Brazilian subjects.
引用
收藏
页数:11
相关论文
共 37 条
[1]   Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis - Results of an international prospective study [J].
Auquier-Dunant, A ;
Mockenhaupt, M ;
Naldi, L ;
Correia, O ;
Schroder, W ;
Roujeau, JC .
ARCHIVES OF DERMATOLOGY, 2002, 138 (08) :1019-1024
[2]   A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions [J].
Barbaud, A. ;
Collet, E. ;
Milpied, B. ;
Assier, H. ;
Staumont, D. ;
Avenel-Audran, M. ;
Grange, A. ;
Amarger, S. ;
Girardin, P. ;
Guinnepain, M. -T. ;
Truchetet, F. ;
Lasek, A. ;
Waton, J. .
BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (03) :555-562
[3]   Expression and Function of Cytochrome P450-Dependent Enzymes in Human Skin Cells [J].
Baron, J. M. ;
Wiederholt, T. ;
Heise, R. ;
Merk, H. F. ;
Bickers, D. R. .
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (22) :2258-2264
[4]   Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper [J].
Brockow, K. ;
Garvey, L. H. ;
Aberer, W. ;
Atanaskovic-Markovic, M. ;
Barbaud, A. ;
Bilo, M. B. ;
Bircher, A. ;
Blanca, M. ;
Bonadonna, B. ;
Campi, P. ;
Castro, E. ;
Cernadas, J. R. ;
Chiriac, A. M. ;
Demoly, P. ;
Grosber, M. ;
Gooi, J. ;
Lombardo, C. ;
Mertes, P. M. ;
Mosbech, H. ;
Nasser, S. ;
Pagani, M. ;
Ring, J. ;
Romano, A. ;
Scherer, K. ;
Schnyder, B. ;
Testi, S. ;
Torres, M. ;
Trautmann, A. ;
Terreehorst, I. .
ALLERGY, 2013, 68 (06) :702-712
[5]   International Consensus on drug allergy [J].
Demoly, P. ;
Adkinson, N. F. ;
Brockow, K. ;
Castells, M. ;
Chiriac, A. M. ;
Greenberger, P. A. ;
Khan, D. A. ;
Lang, D. M. ;
Park, H. -S. ;
Pichler, W. ;
Sanchez-Borges, M. ;
Shiohara, T. ;
Thong, B. Y. -H. .
ALLERGY, 2014, 69 (04) :420-437
[6]   Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins [J].
Edwards, SGM ;
Hubbard, V ;
Aylett, S ;
Wren, D .
POSTGRADUATE MEDICAL JOURNAL, 1999, 75 (889) :680-681
[7]   CHARACTERIZATION OF THE MICROSOMAL EPOXIDE HYDROLASE GENE IN PATIENTS WITH ANTICONVULSANT ADVERSE DRUG-REACTIONS [J].
GAEDIGK, A ;
SPIELBERG, SP ;
GRANT, DM .
PHARMACOGENETICS, 1994, 4 (03) :142-153
[8]   Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations [J].
Goldstein, JA ;
Ishizaki, T ;
Chiba, K ;
deMorais, SMF ;
Bell, D ;
Krahn, PM ;
Evans, DAP .
PHARMACOGENETICS, 1997, 7 (01) :59-64
[9]   Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations [J].
Gonzalez-Galarza, Faviel F. ;
Takeshita, Louise Y. C. ;
Santos, Eduardo J. M. ;
Kempson, Felicity ;
Thomaz Maia, Maria Helena ;
Soares da Silva, Andrea Luciana ;
Teles e Silva, Andre Luiz ;
Ghattaoraya, Gurpreet S. ;
Alfirevic, Ana ;
Jones, Andrew R. ;
Middleton, Derek .
NUCLEIC ACIDS RESEARCH, 2015, 43 (D1) :D784-D788
[10]   GENETIC-ANALYSIS OF MICROSOMAL EPOXIDE HYDROLASE IN PATIENTS WITH CARBAMAZEPINE HYPERSENSITIVITY [J].
GREEN, VJ ;
PIRMOHAMED, M ;
KITTERINGHAM, NR ;
GAEDIGK, A ;
GRANT, DM ;
BOXER, M ;
BURCHELL, B ;
PARK, BK .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (09) :1353-1359